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Background: Toll-like receptor 4 (TLR4) is expressed on immune cells as a sensor that recognizes
lipopolysaccharide (LPS), a microbial conserved component. It has recently been determined that the expression of
TLR4 is also found in various types of tumor cells. Cisplatin is a widely used chemotherapeutic agent for oral
squamous cell carcinoma (OSCC) treatment. However, the mechanisms responsible for cisplatin resistance are not
well understood.
Results: The present study was designed to elucidate the role of TLR4 expression in human OSCC regarding
immune escape and apoptotic resistance to cisplatin. TLR4 and the myeloid differentiation primary response gene
88 (MyD88) were highly expressed in OSCC cell lines. Upon LPS stimulation both NF-κB and p38 MAPK pathways
were activated in OSCC cell lines, followed by the production of large quantities of IL-6, IL-8 and VEGF compared
with human immortalized oral epithelia cells (HIOECs). OSCC cell lines were found to be resistant to
cisplatin-mediated apoptosis after pretreatment with LPS.
Conclusions: Our results suggested that TLR4 was functionally expressed in human OSCC cells and
development of resistance to cisplatin in human OSCC might occur through the mechanism involving TLR4
and its signaling pathway. Suppression of TLR4 and its signaling pathway might thus elevate sensitivity to
cisplatin and potentially help improve the prognosis of patients with OSCC.
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primary response gene 88Background
The prognosis of human oral squamous cell carcinoma
(OSCC) is usually poor with a 5-year survival rate of
approximately 50 ~ 60%, which has generally been attrib-
uted to the insensitivity of most patients to chemother-
apy [1,2]. Recently, there has been a growing recognition
of interest in anti-tumor functions initiated by the innate
immune response. The role of toll-like receptors (TLRs)
and their signaling in tumor immune escape and resist-
ance to apoptosis, for example, is among the frontiers of
exploration [3,4].
TLRs are type I transmembrane proteins with extracel-
lular domains comprised largely of leucine-rich repeats* Correspondence: chenfx@sjtu.edu.cn
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reproduction in any medium, provided the orand intracellular signaling domains that play a crucial role
in inflammation and host defense against invading micro-
organisms through the recognition of pathogen-associated
molecular patterns (PAMPs) such as LPS, lipopeptides,
dsRNA, and bacterial DNA [4]. After binding with ligands,
TLRs and Toll/interleukin-1 receptor-like domain (TIR)
are dimerized and undergo a conformational change that
is required to recruit downstream signaling molecules,
such as MyD88. In mammals, the TLR family consists of
at least 12 members expressed predominantly on the sur-
face of macrophages and various immune cells [5]. LPS is
specifically recognized by TLR4 [6,7]. More recent studies
have demonstrated TLRs expression in a broad variety of
tumor tissues and tumor cell lines [8-11]. Their activated
signaling pathways in cancer cells could have profound
consequences for tumor growth by promoting cancer pro-
gression, anti-apoptotic activity, and resistance to host. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of TLRs in various tumor types, the function of these
receptors in OSCC prognosis and resistance to chemo-
therapy remains unknown [13].
OSCC is sensitive to cisplatin-based chemotherapy in
patients with an initial response to treatment. However,
chemoresistance is observed in the treatment of recur-
rent patients because of acquired or intrinsic resistance.
The main mechanisms and pathways that lead to clinical
resistance to cisplatin in OSCC have not been well
defined. So far, little is known about the function and
biological importance of TLR4 on OSCC chemoresis-
tance. Thus, it is important to address the pattern of
TLR4 expression on OSCC cell lines and to determine
the pathophysiological significance of TLR4 signaling in
the immune escape and chemoresistance of OSCC. The
purpose of this study was to explore the expression and
role of TLR4 in OSCC and how TLR4 signaling corre-
lated with cisplatin resistance in OSCC.
Results
Expression of TLR4 and MyD88 in human OSCC tissues
and cells
To investigate whether TLR4 and its adaptor molecule
MyD88 were expressed in human OSCC tissues, 30
human OSCC specimens and 10 normal oral tissue
samples adjacent to the tumor were assessed in situ in
paraffin sections. In tumor samples, TLR4 was found
to localize to the cell membrane and cell cytoplasm
and MyD88 localized to the cell cytoplasm only. We
also detected the expression of TLR4 and MyD88 in
the normal mucosa adjacent to the tumor, but the ex-
pression was quite weak (Figure 1A). The expression
levels of TLR4 and MyD88 in situ were correlated with
tumor differentiation. TLR4 was highly expressed in
well-differentiated and moderately-differentiated tumors,
but weakly expressed in poorly differentiated tumors
(p = 0.018, Table 1). The expression pattern of MyD88 in
OSCC tumor tissues was similar to that of TLR4
(p = 0.034, Table 1). However, TLR4 and MyD88 expres-
sion were not correlated with other parameters such as
tumor stages, nodal status, tumor size or tumor site.
Additionally, we detected up-regulated TLR4 and
MyD88 mRNA in three OSCC cell lines-HB, CAL-27
and WSU-HN6, compared with HIOEC by RT-PCR as
shown in Figure 1B. Western blot analysis also revealed
high expression of TLR4 and MyD88 in OSCC cell lines
(Figure 1C). Consistent with RT-PCR and Western blot
results, FACS analysis demonstrated that TLR4 expres-
sion in OSCC cell lines was quite high, while the expres-
sion of TLR4 in HIOEC was very low (Figure 1D). Thus,
the different expression levels of TLR4 between HIOEC
and OSCC cell lines suggest that TLR4 may be function-
ally important in human OSCC cells.LPS promotes IL-6, IL-8 and VEGF production via ligation
of TLR4 in human OSCC cells
The cytokines secreted by tumor cells can promote im-
mune suppression and angiogenesis, which in turn even-
tually facilitate tumor survival and metastasis. To
investigate the physiological and pathological roles of
TLR4 in OSCC cells, we treated HIOEC and CAL-27
cells with LPS for 24 h, and then collected the superna-
tants in order to determine the levels of IL-6, IL-8,
VEGF and TGF-β by ELISA. We found that upon LPS
stimulation, CAL-27 cells produced large quantities of
IL-6, IL-8 and VEGF, but the level of TGF-β was not sig-
nificantly changed (Figure 2A). In order to verify the
results obtained by ELISA, we performed RT-PCR and
detected up-regulated mRNA expression for IL-6, IL-8, and
VEGF in CAL-27 cells after LPS stimulation (Figure 2B).
No elevated mRNA expression or secretion of IL-6, IL-8
and VEGF were observed in HIOEC cells after LPS stimu-
lation (Figure 2A and B). In order to verify the necessity of
TLR4 signaling to achieve production and expression of IL-
6, IL-8 and VEGF in human OSCC cell lines induced by
LPS, we tested to see whether TLR4 siRNA could block the
production of these cytokines. TLR4 siRNA was transfected
into CAL-27 cells, followed by stimulation with LPS, and
the result was that the production and expression of IL-6,
IL-8 and VEGF in CAL-27 cells were nearly abolished
(Figure 2C and D). Similar results were obtained for HB
and WSU-HN6 cells (Additional file 1: Figure S1).
LPS activates p38 MAPK and NF-κB signal pathways
through TLR4 in OSCC cells
LPS-triggered TLR4 signaling usually involves two differ-
ent pathways: the p38 mitogen-activated protein kinase
(MAPK) signaling pathway and the NF-κB signaling
pathway. To determine whether LPS could activate p38
MAPK and NF-κB pathways in OSCC cell lines, we trea-
ted OSCC cell lines with LPS for various time periods
followed by protein extraction from the cells. Western
blot analysis showed that p38 MAPK phosphorylation
was induced by LPS in OSCC cell lines as early as
10 min after LPS stimulation (Figure 3A). IL-6, IL-8 and
VEGF expression induced by LPS could be significantly
decreased by p38 MAPK inhibitor PD169316, which
proved that p38 MAPK pathway was involved in the ac-
tivation of OSCC cells through TLR4 (*p< 0.05, com-
pared with LPS stimulation alone, Additional file 1:
Figure S2). Western blot was also used to analyze the ex-
pression of I-κBα in the cell lysates of OSCC cell lines
which had been stimulated with LPS. As shown in
Figure 3A, I-κBα rapidly degraded within 1 h following
stimulation with LPS. Immunofluorescence stain showed
that there was a significant increase in nuclear transloca-
tion of NF-κB subunit p65 after LPS stimulation in
OSCC cell lines (Figure 3B and 3C); the mean
Figure 1 Expression of TLR4 in human OSCC tissues and cell lines. A. Immunohistochemical examination of the expression of TLR4 and
MyD88 in OSCC tissues and adjacent non-malignant epithelia. (a) adjacent non-malignant epithelia; (b) OSCC tissue (magnification × 400). B-D.
TLR4 and MyD88 in HIOEC and OSCC cell lines were analyzed by RT-PCR (B), Western blot (C) and flow cytometry (D). Green line-covered regions
represent isotype controls and red regions represent the detection of TLR4 with mAb.
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a significant increase in OSCC cell lines (Figure 3D),
whereas no changes were observed in HIOEC cells
(Figure 3B-D). Moreover, we detected increased lucifer-
ase activity with the NF-κB luciferase reporter, indicating
the enhanced NF-κB activity in CAL-27 cells with LPS
stimulation (Figure 3E). These findings suggested that
both p38 MAPK and NF-κB signaling pathways were
activated by LPS in human OSCC cells.
In order to further identify whether NF-κB and p38
MAPK pathways were activated by LPS through TLR4,
we silenced TLR4 using siRNA. Transfection of TLR4
siRNA resulted in 80% reduction of TLR4 protein ex-
pression in CAL-27 cells and HB cells (Figure 3F). TLR4
siRNA resulted in partial inhibition of the LPS-induced
activation of NF-κB and p38 MAPK pathways compared
with the negative control siRNA (NC siRNA). At the
same time, a luciferase reporter assay demonstrated thatLPS-induced activation of NF-κB was almost completely
inhibited by TLR4 siRNA compared with that of the NC
siRNA in CAL-27 cells (Figure 3G). These results indi-
cated that LPS-induced activation of NF-κB and p38
MAPK pathways in OSCC cell lines were mediated by
TLR4.
LPS protects OSCC cell lines from cisplatin-induced
apoptosis through TLR4
We explored whether LPS could protect OSCC cells
from cisplatin-induced apoptosis. OSCC cell lines were
pretreated with LPS (1 μg/ml) for 4 h, and then treated
with cisplatin for another 24 h. PI and Annexin V stain-
ing method was used to examine apoptosis. As shown in
Figure 4A, pretreatment of OSCC cells with LPS
decreased the cisplatin-induced cells death and apoptosis,
resulting in a reduction from 18% to 5.6% in CAL-27
cells, 22% to 8.8% in WSU-HN6 cells and 17.8% to 9.1%
Table 1 Correlation between the clinicopathological features and the expressions of TLR4 and MyD88
Characteristics Case no. TLR4 positive grade Nonparametric tests value P.value MyD88 positive grade Nonparametric tests value P.value
Tobacco
Yes 8 1.50 ± 0.92 Z = -0.101 0.919 1.37 ± 0.74 Z = -0.565 0.572
No 22 1.45 ± 0.74 1.59 ± 0.73
Alcohol
Yes 2 2.00 ± 1.41 Z = -0.702 0.472 2.00 ± 1.00 Z = -1.092 0.275
No 28 1.43 ± 1.74 1.5 ± 0.74
Sex
Male 22 1.59 ± 0.73 Z = -1.294 0.196 1.36 ± 0.72 Z = -0.396 0.696
Female 8 1.12 ± 0.83 1.75 ± 1.04
Tumor site
Oral cavity 20 1.55 ± 0.82 χ2=1.635 d.f. = 3 0.652 1.45 ± 0.64 χ2=0.032 d.f. = 3 0.999
Gingiva 4 1.25 ± 0.95 1.5 ± 1.29
Mouth floor 3 1.33 ± 0.57 1.33 ± 1.15
Other 3 1.33 ± 0.57 1.66 ± 1.15
Tumor stage
T1 3 1.66 ± 1.15 χ2=1.698 d.f = 3 0.637 1.66 ± 0.57 χ2=0.498 d.f. = 3 0.919
T2 14 1.57 ± 0.75 1.35 ± 0.74
T3 6 1.50 ± 0.83 1.50 ± 1.04
T4 7 1.14 ± 0.69 1.57 ± 0.97
Nodal status
N0 14 1.57 ± 0.85 Z = -0.495 0.621 1.50 ± 0.65 Z = -0.224 0.823
N1 16 1.37 ± 0.71 1.43 ± 0.96
Pathological differentiation grade
Well 13 1.76 ± 0.72 χ2=8.014 d.f = 2 0.018 1.61 ± 0.76 χ2=6.774 d.f. = 2 0.034
Moderatedly 13 1.61 ± 0.50 1.69 ± 0.75
poorly 4 0.50 ± 0.57 0.50 ± 0.57
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tibility to cisplatin-induced apoptosis while LPS pretreat-
ment showed no protective effect (Figure 4A and 4B).
In order to further examine whether the resistance of
cisplatin-induced apoptosis upon LPS pretreatment was
mediated by TLR4, OSCC cell lines were transfected with
TLR4 specific siRNA or a control siRNA (NC siRNA).
Reduction of cisplatin-induced apoptosis of OSCC cell
lines after LPS pretreatment was abolished when trans-
fected with TLR4 specific siRNA, while NC siRNA could
hardly influence cisplatin-induced apoptosis with LPS
pretreatment (Figure 5). These results indicated that cis-
platin-induced apoptosis decreased by LPS was actually
mediated through TLR4 in OSCC cell lines.
Discussion
We found that TLR4 was expressed in human OSCC
cell lines but not on normal human oral epithelial cells.
The expression levels of TLR4 and MyD88 in situ were cor-
related with tumor differentiation. TLR4 and MyD88 werehighly expressed in well-differentiated and moderately-
differentiated tumors, but weakly expressed in poorly differ-
entiated tumors. Cisplatin is widely used for chemotherapy
of many malignancies, especially for OSCC. However,
the efficiency of cisplatin in the treatment of recur-
rent tumors is limited because of acquired or intrinsic
resistance. In our study, ligation of LPS to TLR4 can
protect cisplatin-induced apoptosis in OSCC cell lines
but not in HIOEC cells. LPS activated NF-κB and
p38 MAPK pathways and triggered target gene tran-
scription. IL-6, IL-8 and VEGF were found to be ele-
vated in OSCC cell lines upon LPS stimulation.
Therefore, OSCC cell lines could respond to oral bac-
teria via the derived LPS, which may lead to apoptotic
resistance to cisplatin.
It is well known that IL-6 production and increased
circulating level have been emerged as biomarkers of
poor prognosis in many human cancers. In ovarian
cancer, increased levels of IL-6 in patients’ sera are
linked to tumor progression, resistance to apoptosis
Figure 2 LPS increased the expression and secretion of IL-6, IL-8 and VEGF through TLR4 in a human OSCC cell line instead of HIOEC
cells. A. HIOEC and CAL-27 cells (5 × 105 ml-1) were stimulated with LPS (1 μg/ml) for 24 h, and then cytokines and chemokines in the
supernatants were assayed using sandwich ELISA. Protein levels (pg/ml) are expressed as mean± SD in three independent experiments
(***p< 0.001, **p< 0.01, *p< 0.05, compared with control). B. RT-PCR analysis of IL-6, IL-8, and VEGF and TGF-β mRNA expression in HIOEC and
CA-27 cells stimulated with LPS (1 μg/ml) for indicated time points. C. To determine the cytokine levels, supernatants were collected from
cultured tumor cells after stimulation with LPS for 24 h with or without TLR4 siRNA transfection. Results are expressed as mean± SD of cytokine
concentrations (pg/ml) in three independent experiments (***p< 0.001, **p< 0.01, *p< 0.05, compared with the NC siRNA group).
D. LPS-induced expression of IL-6, IL-8, and VEGF was inhibited by TLR4 siRNA in CAL-27 cells as determined by RT-PCR.
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tumor angiogenesis and invasion [15-17]. In clinical
investigations, high IL-6 levels in the sera of patients
with colon carcinoma correlate with tumor size [18].
The effect of IL-6 on hepatocyte proliferation depends
on the balance between its pro- and anti-proliferative
arms, after the integration of the effects of other tran-
scription factors acting on the same genes as IL-6
[19]. IL-8 is a proangiogenic cytokine/chemokine and
anti-apoptotic molecule that can promote tumor metas-
tasis and death resistance. IL-8 and VEGF are involved
in the malignant transformation process. It has been
reported that IL-8 is overexpressed in ovarian cancer
and its level is associated with decreased patient sur-
vival and poor clinical outcome [20,21]. VEGF, in
addition to inducing angiogenesis, is also an immuno-
suppressive cytokine that promotes ascite formation
through stimulation of vascular permeability [20,22].
The expression of VEGF is negatively correlated with
DC numbers in the tumor tissue and peripheral blood
of cancer patients [23,24]. Also, VEGF has an inhibitoryeffect on DC differentiation in patients with non-small-
cell lung cancer [25]. Thus, our results show that the
elevated production of IL-6, IL-8 and VEGF in OSCC
cell lines by LPS stimulation may lead to the develop-
ment of resistance to cisplatin in human OSCC.
It is well established that NF-κB is an anti-apoptotic
transcriptional factor upon tumor cell stimulation with
LPS, radiation, and some chemotherapeutic agents.
NF-κB has also been previously linked to upregulation
of anti-apoptotic protein expression and an increase in
cell proliferation [26]. Due to the anti-apoptotic proper-
ties of activated NF-κB, its high expression levels in
tumor cells are associated with tumor progression and
induction of chronic inflammation in the tumor micro-
environment [27]. Activation of NF-κB has been shown
to induce resistance through the expression of the MDR1
gene [28]. It was also reported that LPS could induce
NF-κB activation in colon cancer cells and pancreatic
cancer cells [29,30]. Silencing of TLR4 expression in
SKOV3 cells resulted in sensitization of SKOV3 cells to
PTX-induced apoptosis, and this sensitization was
Figure 3 (See legend on next page.)
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Figure 3 LPS induced activation of p38 MAPK and NF-κB pathways through TLR4 in OSCC cell lines. A. LPS induced p38 MAPK
phosphorylation and I-κBa degeneration for indicated time points in OSCC cell lines. B. HIOEC and OSCC cells plated overnight were stimulated
with LPS (1 μg/ml) for 8 h and then stained as described in Materials and Methods. a to c, control cells were untreated; a and d, nuclei are
stained blue; b and e, the p65 subunit of NF-κB is stained green; c, an overlay of a and b; f, an overlay of d and e. C. Mean± SD of the
percentage of cells with p65 translocation. 200 cells were randomly counted. Results are representative of three independent experiments
performed with each cell line (*p< 0.05, compared with control). D. Mean fluorescence intensity (MFI) of nuclear p65 expression was determined
in OSCC cell lines. Results are expressed as mean ± SD of MFI for three independent experiments performed with each cell line (*p< 0.05,
compared with control). E. Determination of the LPS-activated, NF-κB-dependent transcriptional activity in CAL-27 cells. The cells were transiently
cotransfected with pNF-κB-Luc and pRenilla. Then after 24 h, cells were either left untreated or stimulated with 1 μg/ml of LPS for various times.
Luciferase activity was assessed in the cells (*p< 0.05, compared with control). F. TLR4 was effectively silenced as determined by Western blot
and TLR4 siRNA suppressed the activation of p38 MAPK and NF-κB pathways in OSCC cell lines treated with LPS. G. NF-κB-dependent
transcriptional activity was inhibited by TLR4 siRNA in CAL-27 cells. CAL-27 cells were transiently transfected with NC siRNA and TLR4 siRNA, then
cotransfected with pNF-κB-Luc and pRenilla. 24 h later, the cells were either left untreated or stimulated with 1 μg/ml of LPS for various time.
Luciferase activity was assessed in the cells stimulated with or without LPS. (*p< 0.05, compared with NC siRNA).
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response to PTX and LPS [11]. Inhibition of LPS-induced
TLR4 signaling could improve therapeutic outcomes by
preventing cancer metastasis during the perioperative
period of colorectal cancer resection [31]. In our study,
OSCC cell lines were shown to be resistant to cisplatin-
induced apoptosis upon LPS pretreatment. Moreover,
cisplatin-induced apoptosis decreased by LPS was actu-
ally mediated through TLR4. TLR4 induced NF-κB
pathway activation and nuclear translocation may be
associated with the increased transcription of a number
of different genes and the production of proinflammatory
cytokines such as IL-6, IL-8 and VEGF.
LPS-triggered TLR4 signaling usually activates two dif-
ferent pathways: the NF-κB signal pathway and the p38
MAPK signal pathway. In the cancer cells, Szajnik et al.
demonstrated that activation of NF-κB induced by LPS
was responsible for the production of cytokines such as
IL-6, IL-8 and VEGF in SKOV3 cells [11]. Triggering of
TLR4 by LPS induced tumor promotion by the induc-
tion of proliferation, activation of NF-κB, p65 binding to
DNA, and resistance to NK cell-mediated cytotoxicity
accompanied by the increased production of proinflam-
matory cytokines (IL-6 and IL-8), VEGF [10]. The p38
MAPK pathway has also been shown to be involved in
LPS-induced IL-6 secretion in pituitary adenomas and
bladder cancer cells [29,32]. However, up to now, the
mechanisms by which TLR4 activation with LPS induces
resistance to chemotherapy have not been fully under-
stood. One report showed that inhibition of the NF-κB
pathway can significantly attenuate LPS-induced apop-
tosis resistance [9]. In our present study, we found that
TLR4 ligation can activate both p38 MAPK and NF-κB
pathways in human OSCC cell lines, and inhibition of
TLR4 by siRNA can significantly attenuate LPS-induced
NF-κB and p38 MAPK activation. We also found that
the secretion of cytokines was significantly abrogated by
p38 MAPK specific inhibitor, which proved that p38
MAPK was responsible for LPS induced production ofIL-6, IL-8 and VEGF in OSCC cells. LPS pretreatment
can decrease cisplatin-induced cell death and apoptosis
through TLR4 signaling pathway. On the contrary,
HIOEC cells, which have very low expression levels of
TLR4 and MyD88, did not show these effects. These
findings strongly suggest that LPS can provide a survival
benefit to OSCC cell lines and alter their sensitivity to
cisplatin through activation of p38 MAPK and NF-κB
signaling pathway via TLR4.
Conclusions
In summary, our results indicated that TLR4 was func-
tionally expressed in human OSCC cells and develop-
ment of resistance to cisplatin in human OSCC might
occur through the mechanism involving activation of
TLR4 and its signaling pathway. Suppression of TLR4
and its signaling pathway might thus elevate sensitivity
to cisplatin and potentially help improve the prognosis
of patients with OSCC.
Methods
Cell lines and reagents
The human OSCC cell line CAL-27 used in this study
was obtained from the American Type Culture Collection
(ATCC), which was established in 1982 by J. Gioanni
(Centre Antoine Lacassagne, Nice Cedex, France) from
tissue taken prior to treatment from a 56 year old
Caucasian male with a lesion of the middle of the
tongue. CAL-27 cells are epithelial, polygonal with a
highly granular cytoplasm. The cell line WSU-HN6, a
human OSCC cell line from tongue, was obtained from
the National Institutes of Health (NIH). HIOEC and HB
cells were obtained from the Laboratory of Oral Oncology,
Shanghai Ninth People’s Hospital affiliated to Shanghai
Jiao Tong University, School of Medicine [33,34]. HIOEC
is human immortalized oral epithelial cells, which had
been obtained from normal oral mucosa immortalized by
transfection of HPV16 E6/E7 gene. HB cell was establish
from the HIOEC by induction with benzo(a)pyrene [34].
Figure 4 (See legend on next page.)
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Figure 4 The effects of LPS pretreatment on the cisplatin-induced apoptosis of HIOEC and human OSCC cell lines. A. HIOEC and OSCC
cell lines (5 × 105 ml-1) were pretreated with or without 1 μg/ml LPS for 4 h, then stimulated with 1 μg/ml cisplatin for 24 h. The cells were
stained with Annexin V and PI and subjected to flow cytometry to determine the percentage of Annexin V+PI-/Annexin V+PI+ apoptotic cells.
Results are representative of three independent experiments. B. As depicted, LPS significantly lowered cisplatin-induced apoptosis by elevating
the resistance of OSCC cells but not HIOEC cells. (*p< 0.05, compared with the group treated with cisplatin only).
Sun et al. Molecular Cancer 2012, 11:33 Page 9 of 12
http://www.molecular-cancer.com/content/11/1/33HIOEC cells were maintained in defined keratinocyte-
SFM (Gibco, NY, USA) medium and other cells were
maintained in DMEM supplemented with 10% heat-
inactivated fetal bovine serum (Gibco). All cells were cul-
tured in a humidified atmosphere of 5% CO2 at 37°C. LPS
was obtained from Sigma (MO, USA), and p38 specific in-
hibitor PD169316 was from Abcam (MA, USA).
Specimens and immunohistochemistry
Thirty human OSCC specimens were collected from
patients who had undergone surgery between 2007 and
2009 in the Department of Oral and Maxillofacial Surgery,
Ninth People’s Hospital. All experimental procedures
received ethical approval by the Independent Ethics
Committee of Shanghai Ninth People’s Hospital affiliated
to Shanghai Jiao Tong University, School of Medicine
(Number 200926). Pathological characterization of the
OSCC patients included in this study is summarized in
Table 1. For immunohistochemical examination, OSCC
tissues were fixed with 4% paraformaldehyde and embed-
ded with paraffin. Sections of the samples were blockedFigure 5 Effects of TLR4 siRNA on the cisplatin-induced apoptosis in
(5 × 105 ml-1) were transfected with NC siRNA or TLR4 siRNA for 48 h, pre
1 μg/ml cisplatin for another 24 h. The cells were stained with Annexin V an
Annexin V+PI-/Annexin V+PI+ apoptotic cells. Results are representative of th
cisplatin-induced apoptosis in CAL-27 and WSU-HN6 when TLR4 was silencwith 10% goat serum in PBS and incubated overnight
at 4°C with either anti-TLR4 antibody (Imgenex, CA,
USA) or with anti-MyD88 antibody (Abcam) at a di-
lution of 1:100. After three washes with PBS, the sec-
tions were incubated with peroxidase-conjugated goat
anti-mouse/rabbit antibody for 1 h, followed by incubation
with 3, 3’-Diaminobenzidine (DAB) substrate for 3 min.
Counter-staining was performed with hematoxylin, and
then dehydration was performed with ethanol and di-
methyl benzene. Slides were mounted with Permount
(Santa Cruz, CA, USA) and visualized by Axio Imager
(Zeiss, Oberkonchen, Germany). The IHC results in tis-
sues were scored by two independent investigators based
on the level of staining intensity as follows: none (−): 0%
of stained cells; weak (+): 1-25% of stained cells; moderate
(++): 26-50% of stained cells; strong (+++): >50% of
stained cells.
Reverse transcription-PCR (RT-PCR)
To determine TLR expression at the mRNA level, RT-
PCR was performed. Tumor cells (2× 106) were harvested,human OSCC cell lines. A. CAL-27 and WSU-HN6 cell lines
treated with or without 1 μg/ml LPS for 4 h, then stimulated with
d PI and subjected to flow cytometry to determine the percentage of
ree independent experiments. B. LPS could not decrease the effects of
ed. (*p< 0.05, compared with the group treated with cisplatin only).
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Trizol reagent (Invitrogen, CA, USA). RT-PCR was
performed according to the manufacturer’s instruc-
tions. Reverse transcription was performed with ran-
dom primers using an Omniscript RT kit (Promega,
WI, USA). The sequences of primers for TLR4 were
5’-CAGAGTTGCTTTCAATGGCATC-3’ (forward) and
5’-AGACT GTAATCAAGAACCTGGAGG-3’ (reverse);
and 5’-CTCCTCCACATCCCTTCC-3’ (forward) and
5’-CCGCACGTTCAAGAACAGAGA-3’ (reverse) for
MyD88. PCR was performed using an Expand High
Fidelity PCR System (TaKaRa, Shiga, Japan).
Flow cytometry
TLR4 expression in cells was evaluated by flow cytome-
try as follows: cells were collected and then labeled with
the APC-labeled mouse anti-human TLR4 antibody
(eBioscience, CA, USA) for 30 min at 4°C. The cells
were analyzed using Cell Quest Software. Apoptosis was
measured by flow cytometry as follows: cells were har-
vested and washed in PBS, resuspended in pre-diluted
binding buffer, and stained with AnnexinV-FITC (BD
Biosciences, CA, USA) for 30 min at room temperature.
After being washed and resuspended in PI binding buf-
fer, the cells were immediately subjected to apoptosis
analyses by flow cytometry using Cell Quest Software.
Elisa
Cells (5 × 105 ml-1) were stimulated with 1 μg/ml LPS
for 24 h. Culture supernatants were collected. Cytokines
in the supernatants were measured by ELISA (R&D,
MN, USA) according to the manufacturer’s instructions.
Immunofluorescence microscope
Tumor cells deposited on glass slides were washed twice
with PBS and fixed in 4% paraformaldehyde in PBS for
20 min. The cells were further permeabilized with 0.1%
TritonX in PBS for 8 min, washed and blocked with 5%
bovine serum albumin in PBS for 30 min, then treated
with monoclonal mouse anti-p65 (Santa Cruz) antibody
overnight. FITC-labeled (1:100) anti-mouse IgG served
as the secondary antibody. Sections were then mounted
in a medium containing Hoechst33342 for 5 min to
visualize cell nuclei. Slides were evaluated with a laser
scanning confocal microscope TCS SP2 (Leica, Wetzlar,
Germany), and Adobe Photoshop 7.0 was used for the
digital image analysis.
Luciferase reporter gene assay used to indicate NF-κB
activity
Cal-27 cells were cotransfected with the mixture of
200 ng pNF-κB-Luc and 10 ng pRenilla using the
LipofectamineTM 2000 Reagent (Invitrogen) according to
the manufacturer’s instructions. 24 h after transfection,the cells were either left untreated or stimulated with
1 μg/ml of LPS. Cell lysates were assayed for expression
of luciferase using a dual luciferase assay kit (Promega).
Chemiluminescence, representing the expression of luci-
ferase, was measured in a Junior LB9505 luminometer
(Berthold, Wildbad, Germany). Relative luciferase activ-
ity (RLA) was obtained by normalizing the luciferase ac-
tivity with the pRenilla activity. The extent of NF-κB
activation was represented by the relative increase in the
level of RLA. All transfection experiments were per-
formed in two wells and repeated independently three
times. The activity of controls was set at 1.0.
Western blotting analysis
OSCC cells were stimulated with LPS for various time
periods at 37°C and then lysed with M-PERW Mammalian
Protein Extraction Reagent. Protein was quantified by the
BCA Protein Assay Kit according to the manufacturer’s
instruction, separated by SDS-polyacrylamide gel electro-
phoresis, and then electrotransferred onto a polyvinyli-
dene difluoride membrane. Essential component detection
in the cells was performed with the following antibodies
via overnight incubation at 4°C: anti-MyD88 (Abcam),
anti-I-κBa (Santa Cruz), anti-phosph-p38 (Cell Signaling
Technology, MA, USA), and anti-TLR4 (Imgenex). HRP-
conjugated secondary Antibody (Pierce Chemical, MO,
USA; 1:5000 dilution) was added for 1 h at room
temperature, followed by development of reactions in a
chemiluminescent detection system. β-actin antibody was
used as a control.
Effects of TLR4-specific siRNA
Expression of TLR4 in the cell lines was temporarily
silenced using small interfering RNA (siRNA) of
TLR4. The sense and antisense strands of siRNA
were: 5-GUCUAGUGGCUAAUUCCUA-3 and 5-
UAGGAAUUAGCCACUAGAC-3. Briefly, 2 × 105
tumor cells were seeded in wells of a six-well plate
and cultured in DMEM. The next day, the cells were
transfected with human TLR4 siRNA (GenePharma
Co., Shanghai, China) at different concentrations accord-
ing to the manufacturer’s instructions. The negative con-
trol consisted of siRNA with no homology to known
sequences from humans. Cells were incubated in
complete DMEM medium at 37°C in an atmosphere of
5% CO2. Western blot was used to test TLR4 expression
and further experiments were carried out.
Statistical analysis
Table 1 data were analysed by the statistical software
SPSS10.0 for windows (SPSS10.0 Inc., USA). Other stat-
istical analysis was performed using the Student’s t-test.
Values of P <0.05 were considered significant.
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LPS-induced secretion of cytokines was blocked by the specific p38
MAPK inhibitor PD169316.
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